RNA Therapeutics & Vaccines

RNA therapeutics are programmable medicines whose efficacy, safety, and stability depend on their sequence and delivery system. At Ginkgo, we leverage AI-driven design, high-throughput synthesis, and specialized expertise to optimize mRNA and circRNA sequences for improved durability and protein expression. Our non-viral delivery capabilities include LNP characterization for efficient, targeted delivery with reduced immunogenicity. Partners can also enhance in-house R&D with our mRNA synthesis tools and fee-for-service data generation.

mRNA instability is a key challenge in achieving sustained therapeutic protein expression for mRNA therapeutics and vaccines. To address this, Ginkgo leveraged its machine learning-driven sequence design and high-throughput screening capabilities to design more stable mRNA molecules. The resulting designs were validated in vivo with a different CDS, showing up to 30-100-fold improved protein output, highlighting their potential for clinical translation and therapeutic efficacy.